Wide Ranks

LCTX

Lineage Cell Therapeutics, Inc.

0.5688

Top Statistics
Market Cap 125 M Forward PE -6.09 Revenue Growth -56.30 %
Current Ratio 2.64 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -6.08 Enterprise / Revenue 21.04 Price To Sales Trailing12 Months 20.27
Profitability
Profit Margins 0.00 % Operating Margins -416.69 %
Balance Sheet
Total Cash 38 M Total Cash Per Share 0.2040 Total Debt 2 M
Total Debt To Equity 4.41 Current Ratio 2.64 Book Value Per Share 0.3620
All Measures
Short Ratio 3521.00 % Message Board Id finmb_25622 Shares Short Prior Month 15 M
Return On Equity -0.3504 City Carlsbad Uuid abef1a81-b502-3ba6-9f85-66c1e0506b97
Previous Close 0.6050 First Trade Date Epoch Utc 699 M Book Value 0.3620
Beta 1.28 Total Debt 2 M Volume 3 M
Price To Book 1.57 Last Split Date 878 M Fifty Two Week Low 0.5000
Total Cash Per Share 0.2040 Total Revenue 6 M Shares Short Previous Month Date 1 B
Target Median Price 5.00 Audit Risk 4 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Operating Margins -416.69 %
Last Dividend Value 0.0800 Target Mean Price 4.57 Net Income To Common -24187000
Ask 0.5700 Short Percent Of Float 0.1089 Implied Shares Outstanding 234 M
Last Fiscal Year End 1 B Trailing Peg Ratio None Average Daily Volume10 Day 5 M
Average Volume10days 5 M Total Cash 38 M Next Fiscal Year End 1 B
Revenue Per Share 0.0340 Held Percent Insiders 0.0044 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 1
Regular Market Previous Close 0.6050 Target Low Price 2.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.8478 Open 0.6200 Free Cashflow -8912625
State CA Dividend Yield 0.00 % Return On Assets -0.1286
Time Zone Short Name EST Board Risk 3 Trailing Eps -0.1000
Day Low 0.5649 Address1 2173 Salk Avenue Shares Outstanding 220 M
Compensation Risk 5 Price Hint 4 Target High Price 7.00
Website https://www.lineagecell.com 52 Week Change -0.4184 Average Volume 1 M
Forward Eps -0.1500 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 253.60 % Last Split Factor 3:1 Regular Market Day High 0.6100
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 4.41
Fifty Two Week High 1.61 Day High 0.6100 Shares Short 15 M
Regular Market Open 0.6200 Industry Key biotechnology Bid 0.5300
Earnings Growth 0.00 % Enterprise To Revenue 21.04 Revenue Growth -56.30 %
Shares Percent Shares Out 0.0844 Operating Cashflow -22015000 Currency USD
Time Zone Full Name America/New_York Market Cap 125 M Is_nasdaq_100 False
Zip 92008 Quote Type EQUITY Industry Biotechnology
Long Name Lineage Cell Therapeutics, Inc. Overall Risk 2 Regular Market Day Low 0.5649
Held Percent Institutions 0.5056 Current Price 0.5688 Address2 Suite 200
Enterprise To Ebitda -6.08 Financial Currency USD Current Ratio 2.64
Gross Margins 126.07 % Industry Disp Biotechnology Number Of Analyst Opinions 7
Country United States Float Shares 146 M Two Hundred Day Average 1.00
Governance Epoch Date 1 B Enterprise Value 130 M Price To Sales Trailing12 Months 20.27
Forward PE -6.09 Regular Market Volume 3 M Last Dividend Date 1 B
Ebitda -21397000 Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.

The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.

In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology.

Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme.

The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019.

Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.